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Abstract: Chronic hepatitis C virus (HCV) infection is commonly associated with neurocognitive
dysfunction, altered neuropsychological performance and neuropsychiatric symptoms. Quantifiable
neuropsychological changes in sustained attention, working memory, executive function, verbal
learning and recall are the hallmark of HCV-associated neurocognitive disorder (HCV-AND).
This constellation is at variance with the neuropsychological complex that is seen in minimal hepatic
encephalopathy, which is typified by an array of alterations in psychomotor speed, selective attention
and visuo-constructive function. Noncognitive symptoms, including sleep disturbances, depression,
anxiety and fatigue, which are less easily quantifiable, are frequently encountered and can dominate
the clinical picture and the clinical course of patients with chronic HCV infection. More recently,
an increased vulnerability to Parkinson’s disease among HCV-infected patients has also been reported.
The degree to which neurocognitive and neuropsychiatric changes are due to HCV replication
within brain tissues or HCV-triggered peripheral immune activation remain to be determined.
Without absolute evidence that clearly exonerates or indicts HCV, our understanding of the so-called
“HCV brain syndrome”, relies primarily on clinical and neuropsychological assessments, although
other comorbidities and substance abuse may impact on neurocognitive function, thus confounding
an appropriate recognition. In recent years, a number of functional and structural brain imaging
studies have been of help in recognizing possible biological markers of HCV-AND, thus providing
a rationale for guiding and justifying antiviral therapy in selected cases. Here, we review clinical,
neuroradiological, and therapeutic responses to interferon-based and interferon-free regimens in
HCV-related cognitive and neuropsychiatric disorder.
Keywords: hepatitis C; neurocognitive disorders; MR spectroscopy; diffusion tractography;
functional MRI; PET-CT; SPECT
1. Introduction
Chronic hepatitis C virus (HCV) infection is associated with major hepatic and extrahepatic
complications, including a number of neurological conditions [1,2].
Neuropsychiatric symptoms and neurocognitive dysfunction frequently occur in patients with
chronic HCV infection, independent of liver disease severity or the rate of HCV replication. Sleep
disturbances, depression and fatigue, in addition to reduced quality of life, are often associated with
neurocognitive decline in subjects with non-cirrhotic chronic HCV infection, and may even dominate
the disease course.
Neuropsychological tests have been used for cognitive assessment in HCV-associated
neurocognitive disorder (HCV-AND) and include different batteries for global cognition, frontal-lobe
function, mood, attention, memory and behavioral evaluation.
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HCV-AND shows a profile of prevailing frontal lobe involvement characterized by disordered
executive function, with impairment of working memory, processing speed, set-shifting,
decision-making and verbal fluency [3–6], in association with apathy and disinhibition [7]. Dysfunction
of the prefrontal cortex can also result in alexithymia, the inability to recognize and express one’s feelings,
thus affecting patient-reported symptoms [8].
The attentional function necessitates the complementary action of both frontal and parietal cortices,
with the former involved in the targeting of a particular stimulus (selective attention), and the latter in
maintaining that focus (sustained attention). In HCV-AND, sustained attention seems to be the more
commonly affected subdomain [3], whereas episodic memory per se is relatively less affected, possibly
owing to attentive disturbances and defective encoding strategies [3,9]. An uncommon feature is the
impairment of cognitive domains related to posterior brain regions that affect constructional praxis,
visuo-spatial and visuo-perceptual tasks.
Comorbid conditions, as hepatic encephalopathy (HE) and human immunodeficiency virus
(HIV) infection, could also alter mentation in HCV-infected patients. Minimal HE in particular refers
to the paucisymptomatic cognitive effect of a liver disease of sorts, detectable only with tailored
neuropsychological testing as a prevalent impairment of selective attention, visuo-spatial deficits
with impaired navigation, increased reaction time with executive dysfunction and loss of inhibitory
controls [10]. A multimodal approach is needed to discern the impact of HCV-AND and minimal
HE on cognitive function, with assessment of liver function, instrumental evaluations and extended
neuropsychological testing not exclusively focused on frontal executive function.
Intriguingly, there are also genetic factors that play a role in the development of the neurocognitive
syndromes and neuropsychiatric symptoms in HCV-infected patients. Available data on the
apolipoprotein E (APOE) genotype show that expression of the ε4 allele, an important risk factor for
Alzheimer’s disease and with ε2 of cerebral amyloid angiopathy [11], results in milder impairment in
attention and executive function in HCV-AND [12].
Here we review the spectrum of HCV-related neuroimaging changes associated with cognitive
and neuropsychiatric changes which are subsumed under the terms HCV-AND and “HCV brain
syndrome”, and we also examine the effects of antiviral therapy in subjects treated with old and new
anti-HCV drugs.
The following sections are devoted to different imaging techniques employed in the study of
HCV-AND (Table 1) and obtained results (Table 2).
Table 1. Overview of advanced imaging techniques.
MRS
MRS uses the magnetic resonance signal of a specific atom, usually hydrogen, to evaluate the concentration of selected cerebral
metabolites in a particular volume [13].
Both single voxel and multivoxel assessments can be obtained.
· NAA: a neuronal metabolite. A decreased NAA represents neuronal dysfunction or loss;
· Choline (Cho): as a metabolite expressed in glial and proliferating cells, it is used as a marker of cell membrane turn-over
and, possibly, inflammation;
· Myoinositol (mI): produced only by glial cells, it increases with glial proliferation or with myelin breakdown;
· Creatine (Cr): the reference metabolite, as its concentrations are relatively stable between tissues and conditions. [14]
DTI
DTI evaluates the ordered flow of water molecules, its magnitude and directionality along a restricted path, as it occurs in intact
white matter. Data analysis can be based both on region/voxel-of-interest or on reconstructed neural tracts.
· Fractional anisotropy (FA): the degree of diffusion asymmetry in the different axes. Lower anisotropy represents white
matter damage. Regions of interlacing white matter bundles with different orientations, or asymmetric loss of fibers instead
result in higher anisotropy due to reduced complexity;
· Mean diffusivity (MD): overall spatial restraint due to cellular structures. Injury to any cellular tissue results in
higher diffusivity. [15]
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Table 1. Cont.
MRS
PWI
Neuronal activity directly correlates with brain blood flow in the small capillaries. On PWI, lower local neuronal activity can thus
be observed as lower tissue perfusion, and quantified as cerebral blood volume (CBV) and cerebral blood flow (CBF).
fMRI
fMRI studies the oscillations of cortical activity as a function of subtle alterations in perfusion. The degree of concordance of these
oscillations in between diverse regions suggests a functional coupling, due either to a direct or indirect connection between two
regions [16]. Both resting state connectivity maps and evaluation of the activation pattern evoked by a certain task can be obtained.
Structural MRI
Structure labelling, parcellation and volume quantitation can be obtained with common MRI sequences using appropriate
analytical systems.
18FDG-PET
18FDG-PET uses the metabolic signature of brain structures to investigate neuronal activity.
123I-beta-CIT SPECT
Dopaminergic and serotoninergic pathways can be assessed with 123I-beta-CIT to quantify DAT striatal uptake and SERT
mesencephalic/hypothalamic availability.
11C-(R)-PK-11195 PET
PK-11195 binding is observed in activated microglia, infiltrating macrophages and astrocytes, supporting its use as
an inflammatory marker.
NAA: N-acetyl-aspartate; MRS: magnetic resonance spectroscopy; DTI: diffusion tensor imaging; PWI:
perfusion-weighted imaging; fMRI: functional magnetic resonance imaging; PET: positron emission
tomography; SPECT: single photon emission computed tomography DAT: Dopamine Active Transporter; SERT
Serotonin Transporter.
Table 2. Summary of the imaging findings in HCV-AND.
Nuclear Medicine Response to Treatment
18FDG-PET—Cortical anterior > posterior and cerebellar hypometabolism [17]
11C-(R)-PK-11195-PET—Basal ganglia and thalamic microglial activation [18,19]
123I-CIT-SPECT—Decreased dopaminergic and serotoninergic innervation [17,20]
IFN-α
Decreased anterior metabolism on 18FDG-PET [21]
Inhibited dopamine release in ventral striatum [22]
No effect on serotoninergic innervation [23]
PWI
Cortical anterior > posterior reduced perfusion [24]
Increased basal ganglia perfusion [24]
DAA
Increased basal ganglia perfusion [25]
Structural imaging
Reduced cortical thickness in frontal areas with [26] or without [27] occipital
involvement
Posterior insula and thalamic atrophy [9]
Progressive amygdala and parahippocampal atrophy [9]
DAA
Reduced frontal cortical volumes [28]
DTI
Increased MD and reduced FA in global WM [15] more evident in
fronto-temporal areas [29] and body of CC [9,24,30]
Increased MD in external capsule [4] and fronto-occipital fasciculus [4,9,24]
Decreased FA in bilateral middle cerebellar peduncles [24] and superior thalamic
radiation [31]
Increased FA in the basal ganglia [4]
DAA
Increased FA in association, commissural and projection
tracts [25]
Decreased MD in association and projection tract [25]
fMRI
Altered cortical connectivity possibly due to frontal deficit [32,33]
IFN-α
Reduced ventral striatum activation [22] and global
network efficiency [34]
MRS
Decreased NAA in anterior [35–37] and posterior WM [4,37]
Normal [18,35,37–42] or decreased NAA in cortical GM [43]
Increased Cho in frontal [35,37,38,43,44] and posterior WM [40], cortical GM [45]
and basal ganglia [18,24,40,43,44]
Decreased [41] or normal Cho in basal ganglia [4,42]
Increased mI in frontal WM [4,46], basal ganglia [18,47], cortical GM [45] and
temporal structures [43]
IFN-α
Basal ganglia inflammatory markers:
decrease in groups with increased [48] and normal [42]
baseline values
increase in the group with decreased baseline values [41]
IFN-α: Interferon α; DAA: direct-acting antiviral agents; MD: mean diffusivity; FA: fractional anisotropy; WM:
white matter; CC: corpus callosum; GM: grey matter; Cho: choline; mI: myoinositol.
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2. Imaging in Hepatitis C Virus-Associated Neurocognitive Disorder (HCV-AND)
2.1. Nuclear Medicine
Regional hypometabolism on 18-fluorodeoxyglucose positron emission tomography (18FDG-PET)
in HCV-AND has been observed in anterior cingulate, superior and middle frontal gyri, mainly
correlating with impairment of attention and higher fatigue scores, in addition to the parahippocampal
gyrus and bilateral caudate nuclei, changes associated with anxiety/depression and increased reaction
time on attentive and free recall testing. A relative hypometabolism of part of the cerebellum is also
reported [17], a finding incongruent with pathological studies excluding a direct cerebellar involvement,
and as such, is suggestive of a remote effect of fronto-striatal involvement with reduced cerebellar
innervation, as observed after distant cerebrovascular insults [49].
Diffuse serotoninergic projections from midbrain nuclei modulate the activity of cortical and
subcortical structures, in particular of those involved in the regulation of behavior, mood, and attentive
functions [50]. Conversely, motor activity and decision-making processes are tuned by both cognitive
and emotional abilities, which are mediated by midbrain dopaminergic bundles that reverberate
signals between the cortex and different levels in the basal ganglia [51].
Compared to healthy controls, decreased striatal dopamine transporter uptake (<2 standard
deviations) has been documented in 60% of HCV-infected subjects, and this finding has been associated
with decline in executive-attention tasks [20]. In addition, a positive correlation between striatal
dopaminergic innervation and cerebral metabolism, as evaluated with 18FDG-PET, was also evident
in most cortical areas and basal ganglia [17]. Serotoninergic innervation is similarly affected in 50%
of these patients [20], although modulation of whole brain metabolism has been observed only in
the presence of concomitant dopaminergic impairment [17]. Microglia activation, as assessed with
11C-(R)-PK-11195-PET, is observed in the frontal cortices of HCV-seropositive subjects only in the
presence of peripheral clearance of the virus, and in the temporal cortex in those without concomitant
fatigue [19]. In patients with intact cognition, caudate uptake has been observed, with thalamic uptake
being restricted to selective HCV genotypes [18].
A protective role on cognition of the immune system activation is hinted by an inverse correlation
of the inflammatory response in caudate, putamen and thalami with scores of attention function [19],
although uptake in the same region is also observed to correlate with peripheral blood viral load [18].
Inconclusive data are available on the very early course of HCV infection, evaluated on HIV-infected
cohorts, documenting a normal 11C-(R)-PK-11195-PET profile [47]. A confounding factor to be accounted
for comes from the possibility of concomitant alterations due to HE. On 11C-(R)-PK-11195-PET, HE
usually determines an increased uptake, especially in basal ganglia and the thalamus, that accrues
along with cognitive deterioration [52].
2.2. Perfusion-Weighted Imaging (PWI)
Hypoperfusion due to reduced neuronal activity has been observed in the left frontal cortex and,
to a lesser degree, in the right frontal cortex, the temporoparietal cortices and posterior cingulate gyrus in
a group of naïve HCV-positive subjects with attention impairment. In this group, hyperperfusion of the
basal ganglia suggests immune activation secondary to HCV invasion leading to a vascular response [24],
a phenomenon observed also in other inflammatory conditions, such as multiple sclerosis [53].
2.3. Structural Magnetic Resonance Imaging (MRI)
Several cortical regions demonstrated substantial structural alterations. Left frontal and bilateral
occipital lobe atrophy was noted on cortical thickness assessment, unrelated to the level of fatigue [26].
HCV also accrued the characteristic frontal atrophy of alcohol abuse [27].
On voxel-based morphometry analysis and magnetization transfer ratio, atrophy and cytoarchitectural
alterations were observed in the insular lobe, a structure involved in goal-oriented attention, and in the
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adjacent parietal operculum. Atrophy was also noted in the amygdala and parahippocampal regions
following serial assessments [9].
Alterations have been observed also in structures without proven viral invasion on pathological
studies, suggesting local remodeling due to deafferentation. So far, secondary involvement has been
observed both as atrophic changes, seen in the bilateral thalami, and as pseudohypertrophic changes,
seen in several cerebellar grey matter regions [9].
White matter abnormalities on the other hand have been observed only in HIV/HCV coinfected
subjects [54] but not in paucisymptomatic HCV-monoinfected patients [33].
2.4. Diffusion Tensor Imaging (DTI)
In HCV-infected subjects, reduced local complexity with increased anisotropy is observed in the
basal ganglia, correlating mainly with semantic fluency, and in the bilateral thalami [4]. Thalamic
efferents, as the superior thalamic radiation, also show structural alterations that correlate with
impairment on tests of attention and executive functions [31].
In the normal appearing white matter, Thames et al. observed an altered diffusivity mostly
affecting the external capsule, made up of corticocortical, corticostriatal and striatocortical fibers
connecting the basal ganglia and frontal cortex, and the fronto-occipital fasciculus, involved in semantic
language processes and goal-oriented behavior. Diffusion tensor imaging (DTI) alterations correlate
with frontal white matter inflammatory profile on Magnetic Resonance Spectroscopy (MRS) and poorer
overall performance on neuropsychological testing, in particular in verbal fluency [4]. A similar
pattern of involvement of association tracts with reduced anisotropy in fronto-occipital fasciculus and
anterior commissural fibers has been described also by Bladowska et al. [24] and by Prell et al. using
voxel-based morphometry [9].
Altered DTI indices were also observed in HIV/HCV-coinfected patients in normal appearing
white matter as a whole, with HCV-infected status resulting in widespread alterations of diffusivity and
anisotropy [15]. In particular, reduced anisotropy was observed in frontal and temporal white matter,
and increased diffusivity in temporal and occipitoparietal white matter [29]. HIV/HCV-coinfected
patients also exhibit damage to anterior commissural fibers, with HCV infection accounting for a more
severe involvement of those fibers connecting the primary motor cortices [30]. Lastly, a single study
observed an alteration of middle cerebellar peduncles, possibly secondary to deafferentation [24].
2.5. Magnetic Resonance Spectroscopy (MRS)
Cortical gray matter displays a paucity of alterations on most instances [18,35,37–42] except for
a few MRS studies observing reduced neuronal population as portrayed by lower N-acetyl-aspartate
(NAA) in posterior regions with [43] or without [45] concomitant increases in choline concentration.
Frontal white matter frequently displays increased choline [35,37,38,43,44] or, less frequently,
myo-inositol concentrations that correlate with impairment of executive functions [4,46]. A significant
increase in inflammatory markers is a far less prevalent finding in the posterior white matter [40],
although it still correlates with performances on verbal and visual memory testing [43]. Decreased
neuronal density, on the other hand, is an uncommon observation in both anterior [24,35,36] and
posterior regions [4,37], with the latter correlating with visual memory and visuo-spatial alterations [43].
Neuronal loss in the striatum has been documented in a single study [43] while increased
choline has been commonly observed [18,24,40,43,44] as well as, less often, findings of myo-inositol
elevation [18,47]. Other groups report negative results [4,35,41,42] possibly related to the use of
different sampling methods, with positive results usually exploring a larger voxel placed between
several deep structures. To date, there is an absence of multivoxel studies in HCV-AND to rule out
a heterogenous involvement of these structures. Inconclusive data are available on the very early
course of HCV infection evaluated on HIV-infected cohorts, documenting a normal MRS spectrum [39]
or an isolated scarce increase in myo-inositol [47].
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The significance of inflammation in the striatum is still debated: MRS studies suggest a noxious effect
on the neuropsychological profile [44], in particular affecting attentive and executive functions [18,43,47].
A confounding factor to be accounted for comes from the possibility of concomitant alterations due to HE.
On MRS, a decrease of choline ratio in basal ganglia that correlates with HE severity could be observed [55].
2.6. Functional MRI (fMRI)
An altered function of frontal cortices elicits a remodeling of whole brain networks. On resting
state fMRI, the relative importance of a specific node or cluster of nodes is expressed as centrality,
and an increase of this value is thought to occur as a compensatory response to deficiencies in
other nodes [56]. In HCV-infected patients, involvement of anterior structures is suggested by the
compensatory increase in the right parietal cluster centrality and stronger connectivity in several
temporo-parieto-occipital regions. A deficient frontoparietal attention network is thus relieved by the
posterior regions, hyperactivated to assist in memory and attentive tasks. A successful remodeling
and its efficiency determine the final cognitive profile. Better results demonstrate a positive correlation
with increased centrality in the parietal cluster, as observed in affected subjects only. fMRI remodeling
despite normal gray matter volumes on automated voxel-based whole-brain morphometry suggests
that functional impairment actually predates structural alterations [33]. In other cases, HCV infection
determines more subtle changes: in HCV-infected subjects faced with an obliged choice, impulsive
behavior led to a similar pattern of activation in fronto-parietal areas irrespective of the difficulty of
the choice, whereas in healthy controls an increased activation is observed [32].
Secondary involvement of distant structures can also be detected on fMRI, as higher cerebellar
segregation due to involvement of cerebello-thalamo-cortical circuits [57].
Systemic inflammation, rather than local, can also exert cognitive effects. Increased peripheral blood
prostaglandin E2, an inflammatory biomarker, has been associated with altered connectivity between the
anterior insula and putamen and, in turn, with sickness behavior and increased perceived stress [58].
3. Response to Treatment
3.1. Interferon α (IFN-α)
Until recently, IFN-α and pegylated IFN-α have been the only effective treatments for HCV,
showing rates of sustained virologic response (SVR), i.e., undetectable serum HCV RNA at 24 weeks
after treatment completion, as high as 50–80% when associated with ribavirin [59]. Neuropsychiatric
disturbances are a frequent event during treatment with these agents, with an overall prevalence as
high as 80%, including mood disturbances (depression, irritability), psychosis, suicide ideation and
impairment of cognitive functions [60–62].
Regardless of SVR achievement, transient treatment-induced depression can be observed in up to
half of the patients on medication. The disorder fades with treatment suspension, being persistent at
6 months from the end of the treatment in less than one patient in ten [63]. Risk of further recurrences
of depressive episodes after the treatment course is higher in male patients and those aged above
60 years, more so in case of premorbid anxiety or depressive disorder [64].
Major depressive disorder equally affects HCV-monoinfected and HIV/HCV-coinfected patients
although, unexpectedly, the latter group usually displays less depressive symptoms [65]. Notably,
18FDG-PET studies have shown that, in HCV-infected patients, IFN-α therapy is associated with
decreased metabolic activity prevalent in prefrontal cortices, and the extent of the observed changes
covaries with depression scores [21]. These findings are in keeping with results of EEG spectral analysis
showing anteriorization of alpha waves and increase in parietal theta waves paralleling IFN-induced
depressive symptoms [66]. IFN-α affects in multiple ways the neurotransmitter network involved
in mood regulation, whose description is beyond the scope of this article (see [67], in particular
modulating both serotonin and dopamine pathways. Using 18F-dopa-PET and an fMRI paradigm that
studied the hedonic reward circuitry, after IFN-α administration Capuron et al. observed inhibited
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dopamine release and dampened activation in the ventral striatum that correlated with depressive
symptoms and reduced motivation. In particular, the uptake profile on PET imaging suggested
a functional damage in the absence of frank neuronal loss, as manifested by increased uptake and
decreased turnover of 18F-dopa [22].
A protective effect of IFN-α in HCV-infected subjects against Parkinson’s disease, a disorder
characterized by dopaminergic impairment, is apparent as a reduction in incident cases as early as
5 years from a completed treatment course observed in epidemiological studies [68]. Apart from
an effect on alpha-synuclein deposition, a possibility is that the achievement of SVR results in
a smothering of neuroinflammation thus hampering the neurodegenerative process. The serotonin
pathway, on the other hand, seems not to be affected by IFN-α treatment. A PET study with labeled
3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (11C-DASB), a ligand of the selective
serotonin transporter, failed to disclose any significant differences in presynaptic serotonin transporter
availability or the presence of any correlation with depressive symptoms after 8 weeks of treatment [23].
IFN-α acutely and rapidly affects the brain circuitry, impairing global network efficiency on
a resting state functional MRI connectivity study [34], and resulting in a significant impairment in
executive and learning domains [62]. Aptly timed neurophysiological evaluation with quantitative
EEG testing [66] and event-related potential p300 [66,69] could also be sensitive and inexpensive
methods to quantify IFN-related cognitive impairment.
There is less certainty on the chronic effect of this therapy. Although a normalization in basal
ganglia inflammatory biomarkers on MRS in patients achieving SVR has been observed in both
those groups with increased [42,48] and with decreased baseline values [41], in studies evaluating
clinical outcomes opposing results of improvements on follow-ups in episodic memory, attention
and phonemic verbal fluency [63], and also progressive worsening after treatment completion [59,62],
have been observed. A possible explanation of these divergent outcomes relies on the influence on the
cognitive domains of achieving SVR, and HIV serological status [59,63].
3.2. Direct-Acting Antiviral Agents (DAA)
The treatment of HCV infection has dramatically changed after the availability of direct acting
antivirals, with sofosbuvir being the first widely introduced drug.
IFN-free regimens are generally well tolerated and highly effective, with SVR exceeding 95% in
patients with compensated liver disease that completed the course [70]. Simple dosing and an acceptable
side effect profile result in a good compliance, with >85% patients completing the treatment [71].
Neuropsychiatric side effects are usually limited to insomnia, occurring in <10% patients treated
with direct-acting antiviral agents (DAA). Severe or life-threatening neuropsychiatric symptoms are
rare but could occur, mostly in patients with baseline psychiatric risks. However, the prevalence of
neuropsychiatric symptoms still seems to be lower than that observed during IFN therapy [72].
DAA as a group seems to be effective in alleviating depressive symptoms even in the short-term,
an effect that persists after treatment completion, and with a significantly better profile if compared to
IFN-treated patients [73,74].
A significant improvement in fatigue and depressive symptoms has been observed also in other
studies with different DAAs either alone or in combination with ribavirin [75]. These effects are also
observed when adding simeprevir to an IFN-ribavirin regimen, which results in a shorter worsening
of fatigue and depressive symptoms in treated patients, especially among those achieving SVR [76].
The US National Institute of Health’s Patient-Reported Outcomes Measurement Information
System® (PROMIS®) is a tool used to better standardize the collection of patient-reported information
on health symptoms and health-related quality of life domains, and is freely available [77]. Using this
tool, clinically significant improvements in fatigue, sleep disturbances and functional well-being with
minor improvement in most other assessed health measures were observed after a full course of
treatment with DAAs, with improvement being strongly dependent on the achievement of SVR [78].
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A decrease in the reported cognitive complaints, lamented by 68% of the patients at baseline and
decreasing to 36% at follow-up, is observed with IFN-free therapy in both HCV-monoinfected and
HIV/HCV-coinfected patients. Intriguingly, a normalization in executive function and visual memory
scores on neuropsychological testing was evident as early as 12 weeks from treatment [79]. There are
few other studies that tried to quantify the effects of DAAs on cognitive domains. An improvement
in executive functions and visuospatial ability at a 24-week follow-up visit was observed with
paritraprevir/ombitasvir/ritonavir+dasabuvir in a small group of patients infected with HCV genotype
1. Parallel evaluation with structural MRI disclosed a small reduction in several frontal cortical volumes,
including the subcallosal area, which is involved in memories with emotional and spatial connotations,
in addition to transverse frontopolar gyri, and the anterior segment of the insula [28].
Bladowska et al. observed an improvement in visual memory, executive and visuospatial
domains after a treatment course of paritraprevir/ombitasvir/ritonavir+dasabuvir with or without
ribavirin. DTI and PWI studies in this group also revealed greater anisotropy after therapy in
several association, commissural and projection tracts and lower diffusivity in several association
and projection tracts that correlated with changes in the neuropsychological profile. Higher basal
ganglia perfusion after therapy was also observed, but this finding did not correlate with other
neuropsychiatric and DTI changes [25]. In a pilot study, improvement of working memory, visual
and verbal memory and executive function after treatment with ledipasvir-sofosbuvir correlated with
several inflammatory biomarkers in peripheral blood, such as tumor necrosis factor-α, IFN-γ and
catechol-O-methyl-transferase [80].
Although usually well tolerated, particular groups as cirrhotic patients could show a transient
mild clinical worsening with slower reaction times and an increase in extra-slow components on EEG
after treatment with DAA, unrelated to minimal HE, but resolving at follow-up [81].
4. Summary and Perspectives
HCV-brain syndrome presents as a prominent derangement of attention and executive functions,
associated with neuropsychiatric symptoms. In accordance with this presentation, imaging studies show
a prevalent involvement of frontal cortico-striatal structures and their connections, systems that regulate
the interactions between emotional and motivation regulation, executive and motor functions [82].
At variance with metabolic and hepatic encephalopathy, a direct involvement of the brain is
observed as an inflammatory reaction in these structures. Uncertainty still remains over the clinical
significance of this inflammation, with inconsistent findings of either a noxious or protective effect on
cognition in different studies.
Consistent with current hypotheses of brain circuitry, an altered function is also observed in distant
structures, related to the frontal cortico-striatal network, in the absence of inflammatory findings.
Scarce evidence is available on the reversibility of imaging alterations after treatment, and their
potential use as a biomarker to consider treatment initiation.
HCV-AND is a common complication in HCV-infected subjects and is a leading determinant of
quality of life, although it is often underrecognized due to its subtlety. As effective and well-tolerated
treatments are currently available, imaging biomarkers could assist clinicians in the evaluation of the
cognitive involvement in HCV.
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Abbreviations
HCV
HCV-AND
Hepatitis C virus
HCV-associated neurocognitive disorder
HE
HIV
Hepatic encephalopathy
Human immunodeficiency virus
18FDG
PET
18-fluorodeoxyglucose
Positron Emission Tomography
PWI Perfusion-weighted Imaging
DTI Diffusion Tensor Imaging
MRS Magnetic Resonance Spectroscopy
NAA N-Acetyl-Aspartate
fMRI Functional Magnetic Resonance Imaging
IFN-α Interferon α
SVR Sustained Virological Response
11C-DASB 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile
DAA Direct-acting Antiviral Agents
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